MARC record from Internet Archive

LEADER: 03998cam a22004937a 4500
001 2012952294
003 DLC
005 20130314113132.0
008 121022s2013 gw a b 001 0 eng
010 $a 2012952294
016 7 $a101602969$2DNLM
020 $a9783642335693 (alk. paper)
020 $a3642335691 (alk. paper)
020 $a9783642335709 (ebk.)
035 $a(OCoLC)ocn824603851
040 $aNLM$beng$cNLM$dRUQBL$dOCLCO$dSCB$dAGL$dDLC
042 $anlmcopyc$alccopycat
050 00 $aQP632.B66$bB68 2013
050 14 $aRC350.C54
060 00 $aW1$bCU82K v.214 2013
060 10 $aQV 140
070 0 $aQP632.B66$bB68 2012
082 04 $a615.9/5$a615.95
245 00 $aBotulinum neurotoxins /$cAndreas Rummel, Thomas Binz, editors.
260 $aHeidelberg ;$aNew York :$bSpringer,$cc2013.
300 $aviii, 321 p. :$bill. (some col.) ;$c24 cm.
490 1 $aCurrent topics in microbiology and immunology,$x0070-217X ;$vv.364
504 $aIncludes bibliographical references and index.
505 00 $tGenetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes /$rKaren K. Hill and Theresa J. Smith --$tAssembly and function of the botulinum neurotoxin progenitor complex /$rShenyan Gu and Rongsheng Jin --$tUptake of botulinum neurotoxin in the intestine /$rYukako Fujinage, Yo Sugawara and Takuhiro Matsumura --$tDouble receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity /$rAndreas Rummel --$tThe elusive compass of clostridial neurotoxins : Deciding when and where to go? /$rKinga Bercsenyi, Francesco Giribaldi and Giampietro Schiavo --$tSynchronized chaperone function of botulinum neurotoxin domains mediates light chain translocation into neurons /$rAudrey Fischer --$tClostridial neurotoxin light chains : Devices for SNARE cleavage mediated blockade of neurotransmission /$rThomas Binz --$tSynaptic vesicle proteins : Targets and routes for botulinum neurotoxins /$rGudrun Ahnert-Hilger, Agnieszka Münster-Wandowski and Markus Höltje --$tPersistence of botulinum neurotoxin inactivation of nerve function /$rCharles B. Shoemaker and George A. Oyler --$tStructure-based drug discovery for botulinum neurotoxins /$rSubramanyam Swaminathan --$tComplexity of botulinum neurotoxins : Challenges for detection technology /$rMartin B. Dorner ... [et al.] --$tProgress in cell based assays for botulinum neurotoxin detection /$rSabine Pellett --$tTransforming the domain structure of botulinum neurotoxins into novel therapeutics /$rJohn Chaddock --$tBotulinum toxin : Application, safety, and limitations /$rHans Bigalke.
520 $aThe extremely potent substance botulinum neurotoxin (BoNT) has attracted much interest in diverse fields. Originally identified as cause for the rare but deadly disease botulism, military and terrorist intended to misuse this sophisticated molecule as biological weapon. This caused its classification as select agent category A by the Centers for Diseases Control and Prevention and the listing in the Biological and Toxin Weapons Convention. Later, the civilian use of BoNT as long acting peripheral muscle relaxant has turned this molecule into an indispensable pharmaceutical world wide with annual revenues >$1.5 billion--$cSource other than Library of Congress.
650 0 $aBotulinum toxin.
650 0 $aBotulinum toxin$xTherapeutic use.
650 12 $aBotulinum Toxins, Type A$xtherapeutic use.
650 22 $aBotulinum Toxins, Type A$xpharmacology.
650 22 $aNeuromuscular Agents$xpharmacology.
650 22 $aNeuromuscular Agents$xtherapeutic use.
650 4 $aBotulinum toxin -- Therapeutic use.
650 4 $aBotulinum Toxins -- therapeutic use.
650 6 $aToxines botuliniques.
650 6 $aToxines botuliniques$xEmploi en thérapeutique.
653 $aClostridium
700 1 $aRummel, Andreas.
700 1 $aBinz, Thomas.
830 0 $aCurrent topics in microbiology and immunology ;$v364.$x0070-217X